Total Funding
91
72
Total FundingVenture - Series Unknown raised
Growth Score
4 pts
Heat Score
4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
39035
Cyclarity develops interventions targeting toxic forms of cholesterol to provide true disease-modifying treatments for age-related diseases.
- Michael Kope: CEO Corporate AffairsPast Role: SENS Foundation, Founding Chief Executive Officer
- Matthew ‘Oki’ O’Connor: Co-Chief Executive Officer and Co-founder
About the Company
Cyclarity Therapeuitics is pursuing a mission to treat the underlying causes of age-related disease. The company develops simple and direct interventions targeting toxic oxidized cholesterol, using computationally designed molecules, to provide the first true disease-modifying treatments for age-related diseases such as atherosclerosis,
hypercholesterolemia, heart failure, macular degeneration, and liver failure.
Its products are based on novel derivatives of a well-known, safe compound, and a new way of looking at cardiovascular disease created through a SENS Research Foundation program.
